Brown Shipley& Co Ltd Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Brown Shipley& Co Ltd increased its position in Eli Lilly and Company (NYSE:LLY) by 10.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,544 shares of the company’s stock after acquiring an additional 142 shares during the quarter. Eli Lilly and Company comprises about 0.7% of Brown Shipley& Co Ltd’s holdings, making the stock its 25th biggest holding. Brown Shipley& Co Ltd’s holdings in Eli Lilly and Company were worth $1,368,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. MIG Capital LLC bought a new stake in Eli Lilly and Company during the third quarter valued at $18,234,000. Fiduciary Trust Co raised its holdings in shares of Eli Lilly and Company by 6.5% in the 3rd quarter. Fiduciary Trust Co now owns 8,561 shares of the company’s stock valued at $7,584,000 after acquiring an additional 522 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Eli Lilly and Company by 1.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 509,199 shares of the company’s stock valued at $451,120,000 after acquiring an additional 5,083 shares during the last quarter. First Commonwealth Financial Corp PA grew its holdings in shares of Eli Lilly and Company by 0.8% during the third quarter. First Commonwealth Financial Corp PA now owns 2,056 shares of the company’s stock worth $1,821,000 after purchasing an additional 16 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of Eli Lilly and Company during the third quarter worth about $93,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Bank of America lowered their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Finally, Guggenheim raised their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

LLY opened at $788.35 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The stock’s 50 day simple moving average is $856.96 and its 200 day simple moving average is $869.83. The firm has a market cap of $748.40 billion, a price-to-earnings ratio of 85.23, a PEG ratio of 2.86 and a beta of 0.43. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The firm’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.